Welcome to our dedicated page for vTv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on vTv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a clinical-stage biopharmaceutical company committed to discovering and developing orally administered treatments for metabolic and inflammatory diseases. The company aims to address unmet medical needs through its innovative technology that modulates human proteins into effective medicines. vTv Therapeutics' diverse pipeline includes small molecule clinical and pre-clinical drug candidates targeting a range of conditions such as central nervous system disorders, diabetes, metabolic disorders, inflammation, and cancer.
Leading vTv Therapeutics' pipeline is cadisegliatin (TTP399), an investigational liver-selective glucokinase activator being developed as an adjunctive therapy to insulin for type 1 diabetes (T1D). Cadisegliatin is currently in preparation for Phase 3 clinical trials, with the first study expected to commence in mid-2024. In addition, vTv is exploring further indications for cadisegliatin in type 2 diabetes and other chronic conditions in collaboration with G42 Healthcare Research Technology Projects LLC and IROS, a UAE-based health technology group.
The company has achieved several milestones, including a strategic partnership with Reneo Pharmaceuticals for its PPARδ agonist program. This collaboration includes the potential for significant milestone payments and commercial royalties contingent on the success of Reneo's lead program, mavodelpar.
Apart from its focus on diabetes, vTv Therapeutics is also advancing other promising candidates. These include:
- TTP273: A treatment aimed at metabolic diseases.
- HPP737 and HPP593: Targeting inflammatory disorders.
- Azeliragon: Licensed to Cantex Pharmaceuticals for further development in treating glioblastoma and pancreatic cancer.
vTv Therapeutics continues to build strong financial support, backed by proceeds from strategic sales and investments. Recently, the company secured funds through a private investment in public equity (PIPE) deal to support the upcoming Phase 3 trial of cadisegliatin.
Overall, vTv Therapeutics Inc. is positioned at the forefront of innovative treatments, leveraging its small molecule drug candidates to potentially transform the management of chronic diseases and improve patient outcomes.
FAQ
What is the current stock price of vTv Therapeutics (VTVT)?
What is the market cap of vTv Therapeutics (VTVT)?
What is the main focus of vTv Therapeutics Inc.?
What is cadisegliatin (TTP399)?
What are some other drug candidates in vTv Therapeutics' pipeline?
What is the partnership between vTv Therapeutics and Reneo Pharmaceuticals?
What recent financial moves has vTv Therapeutics made?
When is the Phase 3 trial for cadisegliatin expected to start?
What other conditions are being targeted by vTv's development partners?
What are the potential benefits of the cadisegliatin therapy?
What is azeliragon, and who is developing it?
How does vTv Therapeutics plan to use the proceeds from recent investments?
